Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
about
Regulation of glucose homeostasis by GLP-1Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseAssessment of pancreatic β-cell function: review of methods and clinical applicationsSystems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor SystemGLP-1, the gut-brain, and brain-periphery axesTherapeutic potential of targeting acinar cell reprogramming in pancreatic cancerThe entero-insular axis: implications for human metabolism.Exenatide once weekly: opportunities in the primary care setting.A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.Exenatide Use in the Management of Type 2 Diabetes Mellitus.Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Synthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry.The role of adjunctive exenatide therapy in pediatric type 1 diabetes.Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.The use of exenatide in severely burned pediatric patients.Emerging treatment options for type 2 diabetesExenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.Safety and adverse effects associated with GLP-1 analogues.DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathwayGlucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.Enhanced Peptide Stability Against Protease Digestion Induced by Intrinsic Factor Binding of a Vitamin B12 Conjugate of Exendin-4.Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal.Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 DiabetesTargeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetesPolymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes.Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsGLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunitiesDelivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.Suppression of ROS Production by Exendin-4 in PSC Attenuates the High Glucose-Induced Islet Fibrosis.Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in InsulinomaIncretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.Purification and bioactivity of exendin-4, a peptide analogue of GLP-1, expressed in Pichia pastorisImpact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysisInvestigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
P2860
Q24563430-D74FC984-459D-47A0-8A37-BA42799AC003Q26827183-FABA54F8-C011-45E4-956B-2FCE5C80CFE7Q26829445-05D426CA-BA64-4D9A-8C30-D1F7F4A2DC70Q26999386-4B8F1F32-B5C4-4D1D-875D-E04CA3BC1C2AQ27000749-E823F7F3-EBFB-4101-93ED-DF27F0F69687Q28068998-0ABB35BA-F631-4137-A092-8AAB8F8E7733Q30365939-4144A6F3-9F6D-4322-A6AB-3F44D88AFC33Q30431639-2B1D102F-ECF2-486B-A237-912C4BF69BA3Q33268721-01DF63A3-34EA-43CE-8B32-AFA5CC80AF83Q33603466-410C110F-F926-462B-BC7F-2F621901AE77Q33626001-158CDD37-5BA4-45FB-ABB0-635C4569C72FQ33664114-8D7DD8C1-5901-45F8-9560-90B171DB8747Q33789371-74EFB341-169F-4E01-B1CE-00D3B1AE4D89Q33824522-ACA9CD9C-59BD-49C4-89C5-88BDE7A911DEQ33852418-B01676FC-0FCE-4C88-B770-FBD40E93020FQ33873117-E28BD600-8E2C-45BD-B0B3-8A875FB544EDQ33884913-201DA851-F948-476A-9DF8-EBE0F833340DQ34153353-DB6E5239-A707-43F5-929F-2D4B508B452EQ34381281-8ED5C32A-658E-4E35-A7F9-0A273495A29CQ34530205-4A109F25-D754-4589-AC63-26F690E538F2Q34581781-828096AE-1ACA-4464-9CF3-C9B206B2E732Q35069686-2149BECB-8664-4990-B449-A480678A71BAQ35134808-86D76022-0D39-4B0D-B7F9-A3F59F607639Q35136457-40193853-E106-4223-BDC1-AA39F57D41A0Q35742008-25A1C086-CF61-4573-B73E-D52195DCC9E2Q35794504-B8B60636-8456-46A8-97A3-A187644DE601Q35918380-B8FCD188-79F3-4845-A178-3A8AFE340484Q35962745-E09B8693-6491-49AB-89D1-162076195ED0Q36012896-312E2DD3-C61A-4182-8007-E68A45E5D1FBQ36014423-FD8E92E1-7C1C-42CA-A7FB-46F4B3AC1B10Q36040879-DCD49DDA-B8E0-4E10-A23C-3E2235287107Q36073461-1EFC8DD6-5796-491E-B279-835914727E81Q36153247-E301A066-A0DF-4B61-8C30-FC434F0A20CDQ36186706-E99F9FB8-FDA4-474C-AA5B-A4A0CC29E390Q36224740-6E2C3FF0-45A0-4A22-B471-E533A47C97FEQ36383709-0BD8643A-E225-45A2-9778-0D1E7D3D41F5Q36407215-5C79725D-93A1-462B-B520-2D664ACE916AQ36470199-B3CF9282-65C3-4CAA-B2DE-E38703531D1EQ36520655-48E1A132-4030-4298-BFF9-A45D5CFA9428Q36543063-259CACC6-9DAA-42A9-9C99-6D9531A507B5
P2860
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacology of exenatide (syn ...... ic control of type 2 diabetes.
@ast
Pharmacology of exenatide (syn ...... ic control of type 2 diabetes.
@en
type
label
Pharmacology of exenatide (syn ...... ic control of type 2 diabetes.
@ast
Pharmacology of exenatide (syn ...... ic control of type 2 diabetes.
@en
prefLabel
Pharmacology of exenatide (syn ...... ic control of type 2 diabetes.
@ast
Pharmacology of exenatide (syn ...... ic control of type 2 diabetes.
@en
P2093
P1433
P1476
Pharmacology of exenatide (syn ...... ic control of type 2 diabetes.
@en
P2093
Andrew A Young
David G Parkes
Loretta L Nielsen
P356
10.1016/J.REGPEP.2003.10.028
P577
2004-02-01T00:00:00Z